ETF Holdings Breakdown of AVDL

Stock NameAvadel Pharmaceuticals PLC
TickerAVDL(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS05337M1045

News associated with AVDL

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) Receives Average Recommendation of “Buy” from Brokerages
Avadel Pharmaceuticals PLC. (NASDAQ:AVDL – Get Free Report) has been assigned a consensus recommendation of “Buy” from the six research firms that are covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued a report on the […] - 2025-06-20 06:08:49
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives $19.43 Average Price Target from Analysts
Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) has been assigned an average rating of “Buy” from the seven research firms that are presently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have issued ratings on the stock […] - 2025-05-29 05:43:07
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares Acquired by Deutsche Bank AG
Deutsche Bank AG lifted its holdings in shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) by 6.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 508,696 shares of the company’s stock after acquiring an additional 32,227 shares during the quarter. Deutsche Bank AG’s holdings in Avadel Pharmaceuticals were worth $5,346,000 at the end […] - 2025-05-19 08:07:01
Voya Investment Management LLC Has $296,000 Stock Holdings in Avadel Pharmaceuticals plc (NASDAQ:AVDL)
Voya Investment Management LLC lessened its holdings in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) by 6.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,151 shares of the company’s stock after selling 2,085 shares during the period. Voya […] - 2025-05-12 08:32:50
10,750 Shares in Avadel Pharmaceuticals plc (NASDAQ:AVDL) Purchased by Hsbc Holdings PLC
Hsbc Holdings PLC purchased a new position in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 10,750 shares of the company’s stock, valued at approximately $113,000. A number of other large investors also recently added to or reduced […] - 2025-05-12 07:58:53
Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Gap Up on Earnings Beat
Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) gapped up prior to trading on Wednesday following a stronger than expected earnings report. The stock had previously closed at $8.64, but opened at $9.75. Avadel Pharmaceuticals shares last traded at $9.10, with a volume of 577,848 shares trading hands. The company reported ($0.05) EPS […] - 2025-05-09 05:20:47
Envestnet Asset Management Inc. Decreases Holdings in Avadel Pharmaceuticals plc (NASDAQ:AVDL)
Envestnet Asset Management Inc. trimmed its stake in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) by 54.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,825 shares of the company’s stock after selling 32,618 shares during the quarter. Envestnet […] - 2025-05-07 07:36:50
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Stock Position Raised by MetLife Investment Management LLC
MetLife Investment Management LLC lifted its stake in shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) by 6.1% during the fourth quarter, Holdings Channel reports. The firm owned 57,068 shares of the company’s stock after purchasing an additional 3,271 shares during the quarter. MetLife Investment Management LLC’s holdings in Avadel Pharmaceuticals were worth $600,000 […] - 2025-05-05 08:30:47
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares Acquired by Renaissance Technologies LLC
Renaissance Technologies LLC raised its position in shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) by 1,703.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 387,800 shares of the company’s stock after buying an additional 366,300 shares during the quarter. Renaissance Technologies […] - 2025-04-22 08:45:01
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives $19.88 Average Target Price from Brokerages
Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) has been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage on the […] - 2025-04-09 05:05:03
Teacher Retirement System of Texas Boosts Stake in Avadel Pharmaceuticals plc (NASDAQ:AVDL)
Teacher Retirement System of Texas raised its holdings in shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) by 33.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,738 shares of the company’s stock after purchasing an additional 6,451 shares during the […] - 2025-04-02 07:44:48
Intech Investment Management LLC Raises Position in Avadel Pharmaceuticals plc (NASDAQ:AVDL)
Intech Investment Management LLC lifted its stake in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) by 259.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,758 shares of the company’s stock after purchasing an additional 42,418 shares during the period. Intech Investment […] - 2025-03-25 08:29:10
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives Consensus Recommendation of “Buy” from Analysts
Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) has been given an average rating of “Buy” by the eight ratings firms that are covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued ratings on the stock in the […] - 2025-03-12 06:24:54
Sanctuary Advisors LLC Buys New Stake in Avadel Pharmaceuticals plc (NASDAQ:AVDL)
Sanctuary Advisors LLC bought a new position in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) in the 4th quarter, Holdings Channel reports. The firm bought 13,291 shares of the company’s stock, valued at approximately $140,000. Several other large investors have also modified their holdings of the business. Creative Planning raised its holdings in shares of […] - 2025-03-06 11:52:51
Oppenheimer & Co. Inc. Boosts Stock Holdings in Avadel Pharmaceuticals plc (NASDAQ:AVDL)
Oppenheimer & Co. Inc. boosted its position in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) by 102.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 67,068 shares of the company’s stock after purchasing an additional 33,963 shares during the period. Oppenheimer & Co. Inc.’s holdings in Avadel Pharmaceuticals were worth $705,000 as of […] - 2025-03-06 11:11:30
Needham & Company LLC Reaffirms “Buy” Rating for Avadel Pharmaceuticals (NASDAQ:AVDL)
Needham & Company LLC reiterated their buy rating on shares of Avadel Pharmaceuticals (NASDAQ:AVDL – Free Report) in a research report released on Monday,Benzinga reports. The brokerage currently has a $19.00 price objective on the stock. A number of other brokerages also recently issued reports on AVDL. UBS Group lowered their price objective on Avadel […] - 2025-03-04 06:50:48
Nations Financial Group Inc. IA ADV Purchases Shares of 15,550 Avadel Pharmaceuticals plc (NASDAQ:AVDL)
Nations Financial Group Inc. IA ADV acquired a new position in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 15,550 shares of the company’s stock, valued at approximately $163,000. A number of other institutional investors and […] - 2025-02-19 09:21:08
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives $19.88 Consensus PT from Analysts
Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) have received an average recommendation of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued a […] - 2025-02-18 06:13:05
Avadel Pharmaceuticals (NASDAQ:AVDL) Coverage Initiated at Deutsche Bank Aktiengesellschaft
Analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Avadel Pharmaceuticals (NASDAQ:AVDL – Get Free Report) in a research report issued on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $12.00 price target on the stock. Deutsche Bank Aktiengesellschaft’s price target points to a potential upside of 34.68% from the company’s […] - 2025-02-13 08:22:49

AVDL institutional holdings

The following institutional investment holdings of AVDL have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-26 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 53,549USD 497,470 -1.6%
2025-06-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 49,526USD 460,097
2025-06-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 49,526USD 460,097
2025-06-26 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 70,565USD 655,549
2025-06-26 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 2,842USD 26,402
Total =226,008 USD 2,099,615
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.